ICON PLC (ICLR) - Net Assets
Based on the latest financial reports, ICON PLC (ICLR) has net assets worth $9.33 Billion USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($16.51 Billion) and total liabilities ($7.17 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ICLR intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.33 Billion |
| % of Total Assets | 56.55% |
| Annual Growth Rate | 20.78% |
| 5-Year Change | 414.69% |
| 10-Year Change | 1146.15% |
| Growth Volatility | 64.22 |
ICON PLC - Net Assets Trend (1998–2024)
This chart illustrates how ICON PLC's net assets have evolved over time, based on quarterly financial data. See ICON PLC defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for ICON PLC (1998–2024)
The table below shows the annual net assets of ICON PLC from 1998 to 2024. For live valuation and market cap data, see ICLR market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $9.52 Billion | +3.05% |
| 2023-12-31 | $9.24 Billion | +8.74% |
| 2022-12-31 | $8.50 Billion | +5.34% |
| 2021-12-31 | $8.07 Billion | +335.99% |
| 2020-12-31 | $1.85 Billion | +14.35% |
| 2019-12-31 | $1.62 Billion | +16.71% |
| 2018-12-31 | $1.39 Billion | +12.69% |
| 2017-12-31 | $1.23 Billion | +30.16% |
| 2016-12-31 | $945.17 Million | +23.68% |
| 2015-12-31 | $764.20 Million | -19.58% |
| 2014-12-31 | $950.21 Million | +4.35% |
| 2013-12-31 | $910.58 Million | +20.67% |
| 2012-12-31 | $754.58 Million | +10.72% |
| 2011-12-31 | $681.54 Million | +1.72% |
| 2010-12-31 | $670.00 Million | +17.08% |
| 2009-12-31 | $572.25 Million | +25.39% |
| 2008-12-31 | $456.37 Million | +17.10% |
| 2007-12-31 | $389.71 Million | +28.25% |
| 2006-12-31 | $303.86 Million | +25.33% |
| 2005-12-31 | $242.45 Million | +11.85% |
| 2004-12-31 | $216.76 Million | +82.98% |
| 2003-12-31 | $118.46 Million | -13.47% |
| 2002-12-31 | $136.91 Million | +42.10% |
| 2001-12-31 | $96.35 Million | +20.68% |
| 2000-12-31 | $79.84 Million | +3.61% |
| 1999-12-31 | $77.05 Million | +9.61% |
| 1998-12-31 | $70.30 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ICON PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 14082.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $2.72 Billion | 28.61% |
| Common Stock | $6.59 Million | 0.07% |
| Other Comprehensive Income | $-228.62 Million | -2.40% |
| Other Components | $7.02 Billion | 73.72% |
| Total Equity | $9.52 Billion | 100.00% |
ICON PLC Competitors by Market Cap
The table below lists competitors of ICON PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Futu Holdings Ltd
NASDAQ:FUTU
|
$9.25 Billion |
|
MARKS SPENCER ADR LS-25
F:MA6A
|
$9.25 Billion |
|
RHB Bank Bhd
KLSE:1066
|
$9.25 Billion |
|
Shanghai Putailai New Energy Technology Co.Ltd.
SHG:603659
|
$9.25 Billion |
|
Hindustan Petroleum Corporation Limited
NSE:HINDPETRO
|
$9.24 Billion |
|
DEUTSCHE WOHNEN ADRS/1/2
F:DWNP
|
$9.23 Billion |
|
FSN E-Commerce Ventures Limited
NSE:NYKAA
|
$9.23 Billion |
|
Dr. Reddy's Laboratories Limited
F:RDDA
|
$9.23 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ICON PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 9,240,743,000 to 9,522,999,000, a change of 282,256,000 (3.1%).
- Net income of 791,474,000 contributed positively to equity growth.
- Share repurchases of 499,998,000 reduced equity.
- Other comprehensive income decreased equity by 86,281,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $791.47 Million | +8.31% |
| Share Repurchases | $500.00 Million | -5.25% |
| Other Comprehensive Income | $-86.28 Million | -0.91% |
| Other Changes | $77.06 Million | +0.81% |
| Total Change | $- | 3.05% |
Book Value vs Market Value Analysis
This analysis compares ICON PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.27x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 24.29x to 1.27x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $6.01 | $146.00 | x |
| 1999-12-31 | $3.37 | $146.00 | x |
| 2000-12-31 | $6.67 | $146.00 | x |
| 2001-12-31 | $7.87 | $146.00 | x |
| 2002-12-31 | $11.24 | $146.00 | x |
| 2003-12-31 | $9.73 | $146.00 | x |
| 2004-12-31 | $15.82 | $146.00 | x |
| 2005-12-31 | $8.51 | $146.00 | x |
| 2006-12-31 | $10.49 | $146.00 | x |
| 2007-12-31 | $13.06 | $146.00 | x |
| 2008-12-31 | $7.58 | $146.00 | x |
| 2009-12-31 | $9.55 | $146.00 | x |
| 2010-12-31 | $11.05 | $146.00 | x |
| 2011-12-31 | $11.16 | $146.00 | x |
| 2012-12-31 | $12.43 | $146.00 | x |
| 2013-12-31 | $14.63 | $146.00 | x |
| 2014-12-31 | $15.05 | $146.00 | x |
| 2015-12-31 | $12.68 | $146.00 | x |
| 2016-12-31 | $16.76 | $146.00 | x |
| 2017-12-31 | $22.42 | $146.00 | x |
| 2018-12-31 | $25.33 | $146.00 | x |
| 2019-12-31 | $29.78 | $146.00 | x |
| 2020-12-31 | $34.72 | $146.00 | x |
| 2021-12-31 | $118.51 | $146.00 | x |
| 2022-12-31 | $103.05 | $146.00 | x |
| 2023-12-31 | $111.71 | $146.00 | x |
| 2024-12-31 | $114.69 | $146.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ICON PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.31%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.56%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 1.77x
- Recent ROE (8.31%) is below the historical average (13.93%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | 11.24% | 14.43% | 0.59x | 1.31x | $889.70K |
| 1999 | 7.88% | 7.51% | 0.81x | 1.30x | $-1.64 Million |
| 2000 | 13.77% | 9.45% | 1.05x | 1.39x | $3.01 Million |
| 2001 | 14.74% | 9.07% | 1.06x | 1.54x | $4.57 Million |
| 2002 | 13.35% | 8.10% | 0.96x | 1.72x | $4.59 Million |
| 2003 | 15.43% | 8.10% | 1.21x | 1.58x | $6.44 Million |
| 2004 | 11.88% | 8.67% | 0.89x | 1.55x | $4.07 Million |
| 2005 | 5.26% | 3.67% | 0.99x | 1.45x | $-11.44 Million |
| 2006 | 12.65% | 8.41% | 0.96x | 1.57x | $8.03 Million |
| 2007 | 14.41% | 8.87% | 0.91x | 1.78x | $17.12 Million |
| 2008 | 17.12% | 9.03% | 1.00x | 1.90x | $32.48 Million |
| 2009 | 16.48% | 10.62% | 0.98x | 1.59x | $37.07 Million |
| 2010 | 13.00% | 9.67% | 0.95x | 1.42x | $20.07 Million |
| 2011 | 3.36% | 2.42% | 0.91x | 1.52x | $-45.27 Million |
| 2012 | 7.34% | 4.97% | 0.93x | 1.59x | $-20.04 Million |
| 2013 | 11.29% | 7.70% | 0.93x | 1.58x | $11.75 Million |
| 2014 | 18.15% | 11.47% | 0.98x | 1.61x | $77.45 Million |
| 2015 | 31.35% | 15.21% | 0.92x | 2.25x | $163.12 Million |
| 2016 | 27.74% | 15.73% | 0.91x | 1.93x | $167.66 Million |
| 2017 | 22.88% | 16.01% | 0.80x | 1.78x | $158.46 Million |
| 2018 | 23.28% | 12.44% | 1.09x | 1.72x | $184.18 Million |
| 2019 | 23.11% | 13.33% | 0.97x | 1.80x | $212.18 Million |
| 2020 | 17.72% | 11.72% | 0.81x | 1.86x | $142.79 Million |
| 2021 | 1.90% | 2.79% | 0.32x | 2.16x | $-653.50 Million |
| 2022 | 5.95% | 6.53% | 0.45x | 2.02x | $-344.49 Million |
| 2023 | 6.63% | 7.54% | 0.48x | 1.84x | $-311.74 Million |
| 2024 | 8.31% | 9.56% | 0.49x | 1.77x | $-160.83 Million |
Industry Comparison
This section compares ICON PLC's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $655,728,646
- Average return on equity (ROE) among peers: -117.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ICON PLC (ICLR) | $9.33 Billion | 11.24% | 0.77x | $9.25 Billion |
| Agilent Technologies Inc (A) | $4.63 Billion | -22.30% | 0.77x | $35.96 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $976.24K | -188.19% | 0.03x | $6.13 Million |
| Applied DNA Sciences Inc (APDN) | $8.97 Million | -77.97% | 0.43x | $3.99 Million |
| Biodesix Inc (BDSX) | $20.88 Million | -205.65% | 3.66x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.07 Million | 0.00% | 0.00x | $3.77 Million |
| Biocept Inc. (BIOCQ) | $8.86 Million | -362.16% | 2.48x | $525.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $480.11 Million | 1.55% | 0.32x | $4.36 Billion |
| Burning Rock Biotech Ltd (BNR) | $1.16 Billion | -83.85% | 0.37x | $63.90 Million |
| CareDx Inc (CDNA) | $261.33 Million | -72.81% | 0.79x | $1.13 Billion |
| Check Cap Ltd (CHEK) | $5.91 Million | -165.47% | 0.34x | $9.42 Million |
About ICON PLC
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical stu… Read more